• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Allogene Therapeutics Inc (NQ: ALLO )

    3.050 -0.370 (-10.82%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,728,851
    Open 3.380
    Bid (Size) 2.960 (1)
    Ask (Size) 3.170 (10)
    Prev. Close 3.420
    Today's Range 2.910 - 3.500
    52wk Range 2.010 - 5.775
    Shares Outstanding 142,183,418
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -15.75%
    -15.75%
    1 Month
    +36.77%
    +36.77%
    3 Month
    -11.85%
    -11.85%
    6 Month
    -4.69%
    -4.69%
    1 Year
    -43.62%
    -43.62%

    More News

    Read More
    Analyst Ratings For Allogene Therapeutics
    Via Benzinga
    Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
    Via Benzinga
    Recap: Allogene Therapeutics Q4 Earnings
    Via Benzinga
    Allogene Therapeutics Earnings Preview
    Via Benzinga
    If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
    Via InvestorPlace
    Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
    Via Benzinga
    Topics ETFs
    3 Meme Stocks to Sell and Replace With Meme Coins
    Via InvestorPlace
    Allogene Therapeutics Announces Q2 Investor Conference Participation
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 14, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.